Download PDF
Thromb Haemost 1998; 79(01): 28-31
DOI: 10.1055/s-0037-1614213
Review Article
Schattauer GmbH

Third Generation Oral Contraceptives and Heritable Thrombophilia as Risk Factors of Non-fatal Venous Thromboembolism

Birthe Søgaard Andersen
1   From The Danish Epidemiology Science Centre at the Department of Epidemiology and Social Medicine, University of Aarhus, Aarhus, Denmark
2   Department of Internal Medicine M, Aalborg Hospital, Aalborg, Denmark
,
Jørn Olsen
1   From The Danish Epidemiology Science Centre at the Department of Epidemiology and Social Medicine, University of Aarhus, Aarhus, Denmark
,
Gunnar Lauge Nielsen
1   From The Danish Epidemiology Science Centre at the Department of Epidemiology and Social Medicine, University of Aarhus, Aarhus, Denmark
2   Department of Internal Medicine M, Aalborg Hospital, Aalborg, Denmark
,
Flemming Hald Steffensen
1   From The Danish Epidemiology Science Centre at the Department of Epidemiology and Social Medicine, University of Aarhus, Aarhus, Denmark
2   Department of Internal Medicine M, Aalborg Hospital, Aalborg, Denmark
,
Henrik Toft Sørensen
1   From The Danish Epidemiology Science Centre at the Department of Epidemiology and Social Medicine, University of Aarhus, Aarhus, Denmark
3   Department of Internal Medicine V, Aarhus University Hospital, Aarhus, Denmark
,
John Baech
4   Department of Clinical Immunology, Aalborg Hospital, Aalborg, Denmark
,
Henrik Gregersen
4   Department of Clinical Immunology, Aalborg Hospital, Aalborg, Denmark
› Author Affiliations
Further Information

Publication History

Received 24 June 1997

Accepted after revision 22 August 1997

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Third generation oral contraceptives (OCs) are apparently stronger risk factors for venous thromboembolism (VTE) than other OCs, however, the increased risk may be due to confounding by indication related to differences in prescription behaviour.

We estimated the risk of VTE associated with use of OCs with and without the presence of Factor V Leiden mutation, protein C-, protein S- or antithrombin deficiency.

Sixty-seven cases with VTE were compared with 134 controls. The risk of VTE in the presence of thrombophilia was of the same magnitude for third generation OC users as for users of other OCs; OR: 52.5 (95% CI: 3.7-738.1) and OR: 63.3 (95% CI: 6.2-648.4), respectively.

It is unlikely that confounding by indication entirely explains the risk of VTE associated with third generation OCs since the combined effect exceeds what could be explained if this source of error was the only determinant of the association.

 

  • References

  • 1 World Health Organization Collaborative Study of Cardio vascular Disease and Steroid Hormone Contraception.. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study.. Lancet 1995; 346: 1575-81.
    CrossrefPubMedGoogle Scholar
  • 2 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease.. Lancet 1995; 346: 1582-8.
    CrossrefPubMedGoogle Scholar
  • 3 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components.. Lancet 1995; 346: 1589-93.
    CrossrefPubMedGoogle Scholar
  • 4 Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, Macrae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study.. BMJ 1995; 312: 83-8.
    PubMedGoogle Scholar
  • 5 Committee on Safety of Medicines.. Combined oral contraceptives and thromboembolism.. London: CSM; 1995
    Google Scholar
  • 6 Robinson GE. Low-dose combined oral contraceptives.. Br J Obstet Gynaecol 1994; 101: 1036-42.
    CrossrefPubMedGoogle Scholar
  • 7 Speroff L, De Cherney A. Evaluation of a new generation of oral contraceptives.. Obstet Gynecol 1993; 81: 1034-47.
    PubMedGoogle Scholar
  • 8 Fotherby K, Caldwell ADS. New progestogens in oral contraception.. Contraception 1994; 49: 1-33.
    CrossrefPubMedGoogle Scholar
  • 9 Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progesterons: roles of bias in observational research.. Contraception 1996; 54: 5-13.
    CrossrefPubMedGoogle Scholar
  • 10 Westhoff CL. Oral contraceptives and venous thromboembolism: Should epidemiologic associations drive clinical decision making?. Contraception 1996; 54: 1-3.
    PubMedGoogle Scholar
  • 11 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progesterone.. Lancet 1995; 346: 1593-7.
    CrossrefPubMedGoogle Scholar
  • 12 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.. Lancet 1994; 344: 1453-7.
    CrossrefPubMedGoogle Scholar
  • 13 Pabinger I. Schneider B and the GTH Study Group on Natural Inhibitors.. Thrombosis risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication.. Thromb Haemost 1994; 71: 548-52.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Sørensen HT. Regional administrative health registries as a resource in clinical epidemiology.. A study of options, strengths, limitations and data quality provided with examples of use. Aarhus, 1996. Dissertation.
    PubMedGoogle Scholar
  • 15 International Center of Disease Classification. Eighth Revised edition Copenhagen: Sundhedsstyrelsen; 1977
    Google Scholar
  • 16 International Statistical Classification of Diseases and Health Related Problems. Tenth Revised edition Copenhagen: Sundhedsstyrelsen; 1993
    Google Scholar
  • 17 Preda L, Tripodi A, Valsecchi C, Lombardi A, Finotti E, Mannucci PM. A prothrombin time-based functional assay of protein S.. Thromb Res 1990; 60: 19-32.
    CrossrefPubMedGoogle Scholar
  • 18 Breslow NE, Day NE. Statistical methods in cancer research I: analysis of case-control studies.. Lyon: International Agency for Research on Cancer; 1980
    Google Scholar
  • 19 Vandenbroucke JP, Rosendaal FR. End of the line for “third-generation-pill” controversy?. Lancet 1997; 349: 1113-4.
    CrossrefPubMedGoogle Scholar
  • 20 Lidegaard Ø. Oral contraceptives and cerebral thromboembolism. An epidemiological approach.. Copenhagen: 1996. Dissertation.
    Google Scholar
  • 21 Stubblefield PG. The effects on hemostasis of oral contraceptives containing desogestrel.. Am J Obstet Gynecol 1993; 168: 1047-52.
    CrossrefPubMedGoogle Scholar
  • 22 Daly L, Bonnar J. Comparative studies of 30 g ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.. Am J Obstet Gynecol 1990; 163: 430-7.
    CrossrefPubMedGoogle Scholar